Breaking: FDA panel votes overwhelmingly against MDMA therapy for PTSD

At the end of a nine-hour meeting, the advisory committee voted 10-2 that the data do not show MDMA is effective in treating PTSD.

Log In    Subscribe FDA advisory panel votes overwhelmingly against MDMA therapy for PTSD By Olivia Goldhill and Meghana Keshavan Adobe In a surprisingly strong rejection of the first psychedelic therapy to come before the FDA, a scientific advisory panel on Tuesday overwhelmingly voted against the use of MDMA for treating PTSD.   At the end of a nine-hour meeting marked by sometimes-emotional testimony, the advisory committee voted 10-2 that the data do not show MDMA is effective in treating PTSD. The decision came after members critiqued the methodology of clinical trials by Lykos Therapeutics, which is seeking FDA approval for MDMA, and therapist oversight, rather than the drug itself. READ THE STORY Be the first to know Get instant notifications for the topics and reporters you choose with STAT+ Email Alerts. In Case You Missed It Pharma After MDMA therapy, she considered suicide. The trial data tell a different story Special Report How a device maker inundated pain patients with unwanted batteries and surprise bills A STAT Investigation The doctor would treat her sickle cell pain crisis — if she promised not to get an abortion ALL STORIES STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences   |   Contact Us   |   Advertise With Us